Isabelle Legastelois
Research Subjects
Isabelle Legastelois has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Moste
Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France
3 shared publications Catherine Moste
2 shared publications- Julie Medina
Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France
2 shared publications Régis Sodoyer
B Technology Research Institute Bioaster , Lyon , France
2 shared publications- Régis Sodoyer
Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France; Technology Research Institute Bioaster, 317 Avenue Jean-Jaurès, 69007 Lyon, France
2 shared publications - Adolfo García-Sastre
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 21 December 2016
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (4) , 947-961
Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules
The increasing demand for recombinant vaccine antigens or immunotherapeutic molecules calls into question the universality of current protein expression systems. Vaccine production can require relatively low amounts of expressed materials, but represents an extremely diverse category consisting of different target antigens with marked structural differences. In contrast, monoclonal antibodies, by definition share key molecular characteristics and require a production system capable of very large outputs, which drives the quest for highly efficient and cost-effective systems. In discussing expression systems, the primary assumption is that a universal production platform for vaccines and immunotherapeutics will unlikely exist. This review provides an overview of the evolution of traditional expression systems, including mammalian cells, yeast and E.coli, but also alternative systems such as other bacteria than E. coli, transgenic animals, insect cells, plants and microalgae, Tetrahymena thermophila, Leishmania tarentolae, filamentous fungi, cell free systems, and the incorporation of non-natural amino acids.
- 21 December 2016
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (4) , 947-961
Open AccessNon-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules
The increasing demand for recombinant vaccine antigens or immunotherapeutic molecules calls into question the universality of current protein expression systems. Vaccine production can require relatively low amounts of expressed materials, but represents an extremely diverse category consisting of different target antigens with marked structural differences. In contrast, monoclonal antibodies, by definition share key molecular characteristics and require a production system capable of very large outputs, which drives the quest for highly efficient and cost-effective systems. In discussing expression systems, the primary assumption is that a universal production platform for vaccines and immunotherapeutics will unlikely exist. This review provides an overview of the evolution of traditional expression systems, including mammalian cells, yeast and E.coli, but also alternative systems such as other bacteria than E. coli, transgenic animals, insect cells, plants and microalgae, Tetrahymena thermophila, Leishmania tarentolae, filamentous fungi, cell free systems, and the incorporation of non-natural amino acids.
- 1 February 2014
- Published by Elsevier in Journal of Virological Methods
- Vol. 196, 25-31
Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds
- 1 February 2014
- Published by Elsevier in Journal of Virological Methods
- Vol. 196, 25-31
Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds
- 1 December 2011
- Published by Elsevier in Journal of Virological Methods
- Vol. 178 (1-2) , 129-136
Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines
- 1 December 2011
- Published by Elsevier in Journal of Virological Methods
- Vol. 178 (1-2) , 129-136
Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines
- Open Access
- 1 May 2007
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 1 (3) , 95-104
Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells
Background In case of influenza pandemic, a robust, easy and clean technique to prepare reassortants would be necessary.Objectives Using reverse genetics, we prepared two vaccine reassortants (A/H5N1 × PR8 and A/H7N1 × PR8) exhibiting the envelope glycoproteins from non‐pathogenic avian viruses, A/Turkey/Wisconsin/68 (A/H5N9) and A/Rhea/New Caledonia/39482/93 (A/H7N1) and the internal proteins of the attenuated human virus A/Puerto Rico/8/34 (H1N1).Methods The transfection was accomplished using a mixture of Vero and chicken embryo cells both of which are currently being used for vaccine manufacturing.Results This process was reproducible, resulting in consistent recovery of influenza viruses in 6 days. Because it is mainly the A/H5N1 strain that has recently crossed the human barrier, it is the A/PR8 × A/H5N1 reassortant (RG5) that was further amplified, either in embryonated hen eggs or Vero cells, to produce vaccine pre‐master seed stocks that met quality control specifications. Safety testing in chickens and ferrets was performed to assess the non‐virulence of the reassortant, and finally analysis using chicken and ferret sera immunized with the RG5 virus showed that the vaccine candidate elicited an antibody response cross‐reactive with the Hong Kong 1997 and 2003 H5N1 strains but not the Vietnam/2004 viruses.Conclusions The seeds obtained could be used as part of a pandemic vaccine strain ‘library’ available in case of propagation in humans of a new highly pathogenic avian strain.
- 1 May 2007
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 1 (3) , 95-104
Open AccessPreparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells
Background In case of influenza pandemic, a robust, easy and clean technique to prepare reassortants would be necessary.Objectives Using reverse genetics, we prepared two vaccine reassortants (A/H5N1 × PR8 and A/H7N1 × PR8) exhibiting the envelope glycoproteins from non‐pathogenic avian viruses, A/Turkey/Wisconsin/68 (A/H5N9) and A/Rhea/New Caledonia/39482/93 (A/H7N1) and the internal proteins of the attenuated human virus A/Puerto Rico/8/34 (H1N1).Methods The transfection was accomplished using a mixture of Vero and chicken embryo cells both of which are currently being used for vaccine manufacturing.Results This process was reproducible, resulting in consistent recovery of influenza viruses in 6 days. Because it is mainly the A/H5N1 strain that has recently crossed the human barrier, it is the A/PR8 × A/H5N1 reassortant (RG5) that was further amplified, either in embryonated hen eggs or Vero cells, to produce vaccine pre‐master seed stocks that met quality control specifications. Safety testing in chickens and ferrets was performed to assess the non‐virulence of the reassortant, and finally analysis using chicken and ferret sera immunized with the RG5 virus showed that the vaccine candidate elicited an antibody response cross‐reactive with the Hong Kong 1997 and 2003 H5N1 strains but not the Vietnam/2004 viruses.Conclusions The seeds obtained could be used as part of a pandemic vaccine strain ‘library’ available in case of propagation in humans of a new highly pathogenic avian strain.